- Report
- October 2024
- 193 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,466GBP
- Report
- April 2025
- 80 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- April 2025
- 60 Pages
Global
From €1363EUR$1,500USD£1,158GBP
- Report
- August 2024
- 233 Pages
Global
From €7226EUR$7,950USD£6,136GBP
- Report
- August 2022
- 115 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- January 2024
- 395 Pages
Global
From €6817EUR$7,500USD£5,789GBP
- Report
- April 2023
- 147 Pages
Global
From €4498EUR$4,949USD£3,820GBP
- Report
- August 2022
- 111 Pages
Global
From €4317EUR$4,750USD£3,666GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,045GBP
- Book
- July 2009
- 1116 Pages
Clobazam is a benzodiazepine drug used to treat anxiety, seizures, and other conditions of the central nervous system. It is also used as an adjunct to other anticonvulsants in the treatment of epilepsy. Clobazam is a short-acting drug, meaning it has a rapid onset of action and a short duration of effect. It is metabolized in the liver and excreted in the urine.
Clobazam is available in both generic and brand-name formulations. It is typically prescribed in tablet or liquid form, and is available in a variety of strengths. The drug is also available in combination with other anticonvulsants, such as phenytoin and valproic acid.
The clobazam market is a competitive one, with a number of companies offering the drug. Some of the major players in the market include Pfizer, Novartis, Mylan, and Teva Pharmaceuticals. Other companies, such as Sun Pharmaceuticals, Lupin Pharmaceuticals, and Dr. Reddy's Laboratories, also offer clobazam products. Show Less Read more